Last updated 2026-07-26
- Raised $3.6M Series B led by Eyal Gura, Apr 2026
- Raised Series A led by Arnaud Lorie, Oct 2024
- Raised Seed round led by Fusion VC, May 2023
Total raised
$3.6M
Last: Undisclosed Round 2026-05
Stage
Seed
Founded
2022
Headcount
30
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
MSICS Pharma is an Israeli biotechnology company that develops medical-grade psilocybin for use in therapies targeting complex mental health conditions such as PTSD, treatment-resistant depression, and OCD. The company is the only firm in Israel and Europe licensed to manufacture psilocybin under GMP standards for medical applications, supporting clinical research and use in pharmaceutical settings. They operate a cultivation and production facility using proprietary genetics and technology to produce prescription-grade psilocybin. MSICS Pharma is currently conducting Phase II clinical trials in Israel and plans to launch a multi-center PTSD study with four Israeli hospitals.
Funding history · 3 rounds · $3.6M total
2026-04
B Round
$3.6M
★ Eyal Gura★ Fusion VC★ Shaul Shani★ GlenRock Group
2024-10
A Round
Undisclosed
★ Arnaud Lorie
2023-05
Seed
Undisclosed
★ Fusion VC
Headcount over time
From 3 (2023-10) to 12 (2026-05) · +9 (+300%) · 7 points · source: Finder history + radar grounding
Q&A
- What is MSICS Pharma's primary focus?
- MSICS Pharma is an Israeli biotechnology company focused on pioneering the production of naturally-sourced, medical-grade psilocybin for pharmaceutical applications and clinical trials, targeting complex mental health conditions.
- When was MSICS Pharma founded?
- MSICS Pharma was founded in April 2022.
- What is MSICS Pharma's unique licensing status?
- MSICS Pharma is the only firm in Israel and Europe licensed to manufacture psilocybin under GMP standards for medical applications, supporting clinical research and pharmaceutical use.
- What clinical trials is MSICS Pharma currently conducting?
- MSICS Pharma is currently conducting Phase II clinical trials in Israel and plans to launch a multi-center PTSD study with four Israeli hospitals.
- What was MSICS Pharma's most recent funding round?
- In May 2026, MSICS Pharma completed an A Round, raising $3.6 million. Lead investors included Calmy Investments and Gooday Investments.
- What is the total amount of funding MSICS Pharma has raised to date?
- MSICS Pharma has raised a total of $4.1 million to date.
- How many employees does MSICS Pharma have?
- MSICS Pharma has 11-50 employees.
- Who are the co-founders of MSICS Pharma?
- The co-founders of MSICS Pharma are Roei Zerahia, who serves as CEO, and Omer Zerahia, who is the CBO.
Team · 2
Roei Zerahia
Founder · CEO & Co-Founder
Omer Zerahia
Founder · CBO & Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesRaw Materials
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2B2CB2CB2G
Highlights
Verified
Tags
pharmaceuticalsfungimental-health
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | msicspharma.com |
|---|---|
| linkedin.com/company/97857164 |
Identifiers & details
| Founded | 2022-4 |
|---|---|
| Employees (exact) | 30 |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516237245 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-08-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | צור רמת אפעל 21 רמת גן |